

Jawed Fareed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8839708/publications.pdf>

Version: 2024-02-01

463
papers

6,560
citations

147566

31
h-index

76769

74
g-index

466
all docs

466
docs citations

466
times ranked

10165
citing authors

#	ARTICLE	IF	CITATIONS
1	Arterial-renal Syndrome in Patients with ESRD, a New Disease Paradigm. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110728.	0.7	3
2	Dysregulation of Biomarkers of Hemostatic Activation and Inflammatory Processes are Associated with Adverse Outcomes in Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110648.	0.7	2
3	Analysis of 3-O-Sulfated Heparan Sulfate Using Isotopically Labeled Oligosaccharide Calibrants. Analytical Chemistry, 2022, 94, 2950-2957.	3.2	11
4	The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210917.	0.7	4
5	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962110566.	0.7	13
6	Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate. Pharmaceuticals, 2022, 15, 258.	1.7	20
7	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. Hemato, 2022, 3, 188-203.	0.2	1
8	Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thrombosis Journal, 2022, 20, 20.	0.9	5
9	Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210999.	0.7	2
10	Safety and efficacy of currently used COVID-19 vaccines: Results of a pilot survey. FASEB Journal, 2022, 36, .	0.2	0
11	Molecular and cellular pathogenesis of endothelial lining in atrial fibrillation. FASEB Journal, 2022, 36, .	0.2	0
12	Thrombo-inflammatory Biomarkers in Patients with End Stage Renal Disease. FASEB Journal, 2022, 36, .	0.2	0
13	Collagen Remodeling Proteins, Inflammatory Biomarkers and FABP Regulation in Understanding the Pathogenesis of Atrial Fibrillation. FASEB Journal, 2022, 36, .	0.2	0
14	Bioequivalence of Potency Adjusted Approved Heparin Solutions Compared to a Newly Developed Heparin Solution. FASEB Journal, 2022, 36, .	0.2	0
15	Oxidative Stress Biomarkers in Patients with End Stage Renal Disease. FASEB Journal, 2022, 36, .	0.2	0
16	Quantitative TFPI Antigen Release and Functionality After Intravenous Administration of Heparins Sourced From Various Species in Non-human Primates. FASEB Journal, 2022, 36, .	0.2	0
17	USP Potency Adjusted Bovine Mucosal Heparins are Comparable to Porcine Mucosal Heparin and May be Interchangeable for Anticoagulation. FASEB Journal, 2022, 36, .	0.2	0
18	Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211048.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Regulation of Cortisol in Patients Undergoing Total Joint Arthroplasty. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962198761.	0.7	0
20	National Trends for Peripheral Artery Disease and End Stage Renal Disease From the National Inpatient Sample Database. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110256.	0.7	1
21	Biomarkers of Platelet Activation and Their Prognostic Value in Patients With Sepsis-Associated Disseminated Intravascular Coagulopathy. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962094330.	0.7	17
22	Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors—An In Vitro Study. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110211.	0.7	2
23	Time Course of Inflammatory and Procoagulant Markers in the Early Period After Total Hip Replacement. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962098594.	0.7	3
24	Interrelationship of MMP-9, Proteoglycan-4, and Inflammation in Osteoarthritis Patients Undergoing Total Hip Arthroplasty. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962199556.	0.7	7
25	Upregulation of Inflammatory Cytokines in Pulmonary Embolism Using Biochip-Array Profiling. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110131.	0.7	12
26	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110214.	0.7	29
27	The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962095083.	0.7	9
28	Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110149.	0.7	2
29	Rotational thromboelastometry (ROTEM) profiling of COVID-19 patients. Platelets, 2021, 32, 690-696.	1.1	27
30	COVID-19-induced endothelitis: emerging evidence and possible therapeutic strategies. British Journal of Haematology, 2021, 193, 43-51.	1.2	49
31	Biomarkers, inflammation, and thrombosis in Hepatocellular Carcinoma. FASEB Journal, 2021, 35, .	0.2	0
32	Biomarkers of Inflammation and Thrombosis in Patients Undergoing Total Joint Replacement. FASEB Journal, 2021, 35, .	0.2	0
33	Quantification of Bovine and Porcine Heparins Utilizing the Heparin Red Assay, Applications in the Study of Pharmacokinetics and Pharmacodynamics. FASEB Journal, 2021, 35, .	0.2	0
34	Do we have a unified consensus on antithrombotic management of PAD?. International Angiology, 2021, 40, 229-239.	0.4	1
35	Comparison of Functional Methods with Absolute Quantitation of Heparin Levels in Clinical Samples as measured by Heparin Red Assay. FASEB Journal, 2021, 35, .	0.2	0
36	Novel CT-derived parameter is associated with low cardiac index in acute pulmonary embolism. Thrombosis Research, 2021, 202, 105-107.	0.8	2

#	ARTICLE	IF	CITATIONS
37	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007.	1.8	21
38	Comparison of outcomes in catheter-directed versus ultrasound-assisted thrombolysis for management of submassive pulmonary embolism. <i>Thrombosis Research</i> , 2021, 202, 96-99.	0.8	8
39	Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 423-433.	1.5	6
40	Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 203-212.	3.6	28
41	Protamine Sulfate Neutralization Profile of Various Dosages of Bovine, Ovine and Porcine UFHs and Their Depolymerized Derivatives in Non-Human Primates. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110055.	0.7	2
42	Combined Vaccination Approaches for COVID-19. Will These Improve the Efficacy Spectrum?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110339.	0.7	0
43	Neurological Complications of Pulmonary Embolism: a Literature Review. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 59.	2.0	7
44	The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110503.	0.7	0
45	Fibrinolytic Dysregulation Contributes to the Hypercoagulable State in Pulmonary Embolism Patients. <i>Blood</i> , 2021, 138, 3177-3177.	0.6	0
46	Impact of LMWH and Specific Factor Xa Inhibitors, Apixaban and Fondaparinux, on Cancer Cell Biology and Procoagulant Properties of Cancer Microenvironment. <i>Blood</i> , 2021, 138, 2136-2136.	0.6	1
47	Prospective Assessment of Biomarkers of Hypercoagulability in Oncological Patients and Healthcare Workers Following Vaccination Against Sars-Cov-2 with the mRNA Vaccine. the Roadmap-COVID-19-Vaccin Study. <i>Blood</i> , 2021, 138, 3207-3207.	0.6	0
48	USP Standardized Mixtures of Bovine, Ovine and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single Sourced Heparins and May be Interchangeable,. <i>Blood</i> , 2021, 138, 1067-1067.	0.6	3
49	Utility of Blood Cellular Indices in the Risk Stratification of Patients Presenting with Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110522.	0.7	3
50	Public Perceptions of Current COVID-19 Vaccinations. Results of a Pilot Survey. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110669.	0.7	4
51	Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096082.	0.7	2
52	Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	5
53	Viral Coagulopathy in Patients With COVID-19: Treatment and Care. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093677.	0.7	64
54	Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093552.	0.7	15

#	ARTICLE	IF	CITATIONS
55	Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. <i>Critical Care Medicine</i> , 2020, 48, 1140-1147.	0.4	34
56	Response to Maccio et al, "Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrinolytics have a role in the early phases of coagulation disorders?" <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3111-3113.	1.9	10
57	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628.	1.8	131
58	Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095491.	0.7	9
59	Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095185.	0.7	2
60	Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096459.	0.7	2
61	P1077PERSISTENCE OF CIRCULATING RESIDUAL HEPARIN IN ESRD PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
62	P1403PLASMA OSTEOPOINTIN LEVELS DIRECTLY CORRELATE WITH INTACT PARATHYROID HORMONE AND ALKALINE PHOSPHATE LEVELS IN END STAGE RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
63	Difficulties of Managing Submassive and Massive Pulmonary Embolism in the Era of COVID-19. <i>JACC: Case Reports</i> , 2020, 2, 1383-1387.	0.3	10
64	Structural characterization of a clinically described heparin-like substance in plasma causing bleeding. <i>Carbohydrate Polymers</i> , 2020, 244, 116443.	5.1	6
65	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
66	Procalcitonin as a Marker of Comorbid Atrial Fibrillation in Chronic Kidney Disease and History of Sepsis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093222.	0.7	4
67	Development of an Algorithm to Predict Mortality in Patients With Sepsis and Coagulopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962090284.	0.7	5
68	Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093635.	0.7	25
69	Relationship Between 25-Hydroxyvitamin D, Renin, and Collagen Remodeling Biomarkers in Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961989970.	0.7	6
70	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict All-Cause Mortality in Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961990054.	0.7	30
71	Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602961989512.	0.7	13
72	Vascular endothelial growth factor in bipolar depression: A potential biomarker for diagnosis and treatment outcome prediction. <i>Psychiatry Research</i> , 2020, 284, 112781.	1.7	13

#	ARTICLE	IF	CITATIONS
73	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
74	Interrelationship of Osteopontin, MMP-9 and ADAMTS4 in Patients With Osteoarthritis Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962096486.	0.7	15
75	Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962098346.	0.7	1
76	Differential Augmentation of Thrombin Generation by Andexanet Alfa in Lymphoma Patients. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
77	Profiling of Inflammatory Biomarkers and Coagulation Factors in End-Stage Renal Disease. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
78	Altered Coagulation Parameters and D-Dimer Measurements in Sepsis are useful in Scoring the Risk Stratification. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
79	Discordance between the neutralization profile of apixaban, betrixaban, edoxaban and rivaroxaban in the clotting assays and anti-Xa measurements. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
80	Decreased Thrombin Generation Potential in Lymphoma Patients is associated with Increased D-dimer, CRP, vWF and TNF- α . Interrelationship between Thrombogenesis and Inflammation. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
81	Biological and Pharmacological Profiling of Pentosan Polysulfate (PPS) in Comparison to Heparin and its Relative Neutralization by Protamine Sulfate. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
82	Molecular Pathogenesis of Bone Degenerative Disease and Associated Inflammatory Processes. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
83	Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Antiheparin Platelet Factor 4 Antibodies as Studied in Platelet Aggregation Assays. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
84	Heparinox, a generic version of low molecular weight heparin enoxaparin, is bioequivalent to the branded version. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.2	0
85	Assay Dependent Reversal of the Oral and Parenteral Anti-Xa Agents By Andexanet Alfa. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
86	Malignant Clonal Cell Proliferation in Multiple Myeloma and the Hypercoagulable State. <i>Blood</i> , 2020, 136, 23-24.	0.6	0
87	Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group. <i>Blood</i> , 2020, 136, 6-8.	0.6	1
88	Validation of the Bioequivalence of USP Potency Adjusted Porcine, Ovine, and Bovine Heparins. <i>Blood</i> , 2020, 136, 6-6.	0.6	0
89	Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication. <i>Blood</i> , 2020, 136, 8-8.	0.6	1
90	Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961986349.	0.7	18

#	ARTICLE	IF	CITATIONS
91	Anticoagulant activity of porcine heparin: Structural-property relationship and semi-quantitative estimation by nuclear magnetic resonance (NMR) spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 639-643.	1.4	11
92	Crude Heparin Preparations Unveil the Presence of Structurally Diverse Oversulfated Contaminants. <i>Molecules</i> , 2019, 24, 2988.	1.7	5
93	Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome. <i>International Angiology</i> , 2019, 38, 17-21.	0.4	9
94	Porcine Mucosal Heparin Shortage Crisis! What Are the Options?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987878.	0.7	15
95	Zika and Chikungunya Virus and Risk for Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961882118.	0.7	51
96	Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985643.	0.7	3
97	Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985216.	0.7	40
98	Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1993.	3.8	221
99	Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984752.	0.7	19
100	Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984070.	0.7	8
101	Systematic analysis of enoxaparins from different sources with online one- and two-dimensional chromatography. <i>Analyst</i> , The, 2019, 144, 3746-3755.	1.7	8
102	Markers of Inflammation and Infection in Sepsis and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984333.	0.7	60
103	The Risk of Venous Thromboembolism is Not Equal for all Patients Who Undergo Total Joint Replacement. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983806.	0.7	4
104	Matrix Metalloproteinases and Their Inhibitors and Proteoglycan 4 in Patients Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961982811.	0.7	14
105	Attenuation of Postmeal Metabolic Indices with Red Raspberries in Individuals at Risk for Diabetes: A Randomized Controlled Trial. <i>Obesity</i> , 2019, 27, 542-550.	1.5	36
106	Right Ventricular Outflow Doppler Predicts Low Cardiac Index in Intermediate Risk Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988606.	0.7	24
107	Comparative Pharmacological Profiles of Various Bovine, Ovine, and Porcine Heparins. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988940.	0.7	12
108	Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961989662.	0.7	6

#	ARTICLE	IF	CITATIONS
109	Chemometric analysis of porcine, bovine and ovine heparins. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 345-352.	1.4	16
110	Biomarkers of Hemostatic Activation and Inflammation Are Associated with Altered Coagulation Parameters in Sepsis Patients. Blood, 2019, 134, 2401-2401.	0.6	1
111	Comparative Studies on the Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies. Blood, 2019, 134, 2446-2446.	0.6	1
112	Differential Neutralization of Unfractionated Heparin, Enoxaparin and Fondaparinux by Andexanet Alpha. FASEB Journal, 2019, 33, 819.12.	0.2	0
113	A Generic Recombinant Factor VIIa is Comparable to the Branded Novoseven in In Vitro and Pharmacokinetic Studies in Primates. FASEB Journal, 2019, 33, 515.4.	0.2	0
114	A Factor Xa Inhibitor Antidote (andexanet alfa) is Capable of Neutralizing the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin in a Comparable Manner as Protamine Sulfate. FASEB Journal, 2019, 33, 1b37.	0.2	0
115	Coagulation and Circulating Heparin Profile in Patients with End Stage Renal Disease Undergoing Maintenance Hemodialysis. FASEB Journal, 2019, 33, 1b406.	0.2	0
116	Ovine Mucosal Enoxaparin Exhibit Comparable Pharmacokinetic Profiles to Porcine Mucosal Enoxaparin. FASEB Journal, 2019, 33, 515.12.	0.2	0
117	Comparative Studies on the Oral Anticoagulant Activities of Orally Active Anti-Xa and Anti-IIa Agents in Whole Blood and Plasma and their Neutralization by FEIBA. FASEB Journal, 2019, 33, 515.2.	0.2	0
118	A Comparison of GMP Manufactured Ovine Mucosal Enoxaparin and Branded Porcine Enoxaparin. FASEB Journal, 2019, 33, 515.11.	0.2	0
119	Reversal of the Thrombin Generation Inhibitory Effect of Apixaban, Betrixaban, Edoxaban and Rivaroxaban by Andexanet Alpha may be Associated with Increased Thrombogenesis. FASEB Journal, 2019, 33, 515.1.	0.2	0
120	Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma: Potential Relevance to Thrombogenesis. FASEB Journal, 2019, 33, 250.11.	0.2	0
121	Differential Effects of Dabigatran, Rivaroxaban, Apixaban, Edoxaban and Betrixaban on Fibrinokinetics and their Modulation by FEIBA. FASEB Journal, 2019, 33, 819.13.	0.2	0
122	Potency Adjusted Bovine Heparin is Comparable to Porcine Heparin in Patients Undergoing Open Heart Surgery. FASEB Journal, 2019, 33, 819.8.	0.2	0
123	Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux. Blood, 2019, 134, 1158-1158.	0.6	1
124	Neutrophil to Lymphocyte Ratio (NLR), Platelet to Lymphocyte Ratio (PLR) and Risk of Thromboembolism in Patients with Lymphoma. Blood, 2019, 134, 3649-3649.	0.6	0
125	Predictive Value of Cellular Blood Indices for All-Cause Mortality in Acute Pulmonary Embolism. Blood, 2019, 134, 2103-2103.	0.6	0
126	Prothrombinase Induced Clotting Time Is More Sensitive than aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma. Blood, 2019, 134, 3374-3374.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma: Potential Relevance to Thrombogenesis. <i>Blood</i> , 2019, 134, 4945-4945.	0.6	4
128	USP Potency Adjusted Bovine Mucosal Heparins (BMH) Are Comparable to Porcine Mucosal Heparin (PMH) at Equivalent Levels. <i>Blood</i> , 2019, 134, 165-165.	0.6	1
129	Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects. <i>Blood</i> , 2019, 134, 3665-3665.	0.6	1
130	Dysregulation of Hemostatic Biomarkers, Inflammatory Biomarkers, and Alteration of Cellular Indices As Predictors of Adverse Outcomes in Pulmonary Embolism Patients. <i>Blood</i> , 2019, 134, 2408-2408.	0.6	0
131	Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-Dimer, CRP, Vwf and TNF- α . Interrelationship between Thrombogenesis and Inflammation. <i>Blood</i> , 2019, 134, 5239-5239.	0.6	0
132	Differential Neutralization of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban By Andexanet Alfa As Measured By Whole Blood Thromboelastographic Analysis. <i>Blood</i> , 2019, 134, 1155-1155.	0.6	0
133	Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 803-807.	0.7	6
134	Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 859-866.	0.7	5
135	Inflammatory Biomarker Profiling in Total Joint Arthroplasty and Its Relevance to Circulating Levels of Lubricin, a Novel Proteoglycan. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 950-959.	0.7	12
136	Improving reliability of chemometric models for authentication of species origin of heparin by switching from 1D to 2D NMR experiments. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 153, 168-174.	1.4	10
137	Postoperative Changes in the Systemic Inflammatory Milieu in Older Surgical Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 583-588.	0.7	6
138	Biomarkers of Inflammation, Thrombogenesis, and Collagen Turnover in Patients With Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 718-723.	0.7	22
139	Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator. <i>Journal of Vascular Surgery</i> , 2018, 67, 294-299.	0.6	4
140	Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 625-632.	0.7	25
141	Authentication of animal origin of heparin and low molecular weight heparin including ovine, porcine and bovine species using 1D NMR spectroscopy and chemometric tools. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 114-119.	1.4	31
142	Levels of Matrix-Degrading Enzymes and Lubricin in Patients With Degenerative Joint Disease Requiring Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 41-46.	0.7	5
143	Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 235-240.	0.7	18
144	Elevated extracellular nucleosomes and their relevance to inflammation in stage 5 chronic kidney disease. <i>International Angiology</i> , 2018, 37, 419-426.	0.4	4

#	ARTICLE	IF	CITATIONS
145	FP327ELEVATED LEVELS OF EXTRACELLULAR NUCLEOSOMES, BIOMARKERS OF CELL DEATH, IN STAGE 5 CHRONIC KIDNEY HEMODIALYSIS (CKD5-HD) ARE INDEPENDENT OF CIRCULATING TISSUE FACTOR MICROPARTICLE COMPLEX. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i140-i141.	0.4	0
146	SP272PROFILING OF NEUROVASCULAR DISEASES IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE USING SPECIFIC BIOMARKER PROFILING. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i435-i435.	0.4	0
147	Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 314S-322S.	0.7	0
148	Biomarker Profiling of Neurovascular Diseases in Patients with Stage 5 Chronic Kidney Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 248S-254S.	0.7	0
149	Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial. <i>International Angiology</i> , 2018, 37, 427-430.	0.4	3
150	International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treatment and Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1033-1041.	0.7	8
151	Disseminated Intravascular Coagulation: An Update on Pathogenesis, Diagnosis, and Therapeutic Strategies. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 8S-28S.	0.7	114
152	Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiotensin-2 and Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 269S-276S.	0.7	8
153	Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. <i>International Angiology</i> , 2018, 37, 255-260.	0.4	2
154	Advances in Heparins and Related Research. An Epilogue. <i>Molecules</i> , 2018, 23, 390.	1.7	5
155	Angiotensin 2 Levels in the Risk Stratification and Mortality Outcome Prediction of Sepsis-Associated Coagulopathy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1223-1233.	0.7	18
156	Vitamin D and Postoperative Vasopressor Use in Cardiopulmonary Bypass. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1322-1326.	0.7	5
157	Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels. <i>Frontiers in Medicine</i> , 2018, 5, 360.	1.2	15
158	Relative Neutralization of Heparin from Different Origins by Protamine, Polybrene, Platelet Factor 4, and synthetic heparin antagonist PMX. <i>FASEB Journal</i> , 2018, 32, 570.8.	0.2	0
159	Heparins Derived from Ovine (Sheep) Mucosa are Interchangeable to their Porcine (Pig) Counterparts. <i>FASEB Journal</i> , 2018, 32, 701.5.	0.2	0
160	Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 725-734.	0.7	14
161	Comparison of Low-Molecular-Weight Heparins Prepared From Bovine Heparins With Enoxaparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 542-553.	0.7	21
162	Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease. <i>International Journal of Angiology</i> , 2017, 26, 043-048.	0.2	5

#	ARTICLE	IF	CITATIONS
163	Dysregulation of Tissue Factor, Thrombin-Activatable Fibrinolysis Inhibitor, and Fibrinogen in Patients Undergoing Total Joint Arthroplasty. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 967-972.	0.7	11
164	Reversal of new oral anticoagulants and personalized medicine. <i>Personalized Medicine</i> , 2017, 14, 5-7.	0.8	0
165	Synthetic oligosaccharides can replace animal-sourced low molecular weight heparins. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	82
166	Thrombomodulin alfa attenuates the procoagulant effect and cytotoxicity of extracellular histones through the promotion of protein C activation. <i>Thrombosis Research</i> , 2017, 160, 51-57.	0.8	9
167	Betrixaban for VTE Prevention in the Medically Ill Population, the APEX Trial: Good News for This Needy Population?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 701-702.	0.7	3
168	Recombinant Factor VIIa Mediated Activation of Prothrombin Complex Concentrates. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 211-220.	0.7	1
169	The Protective Effect of Poloxamer-188 on Platelet Functions. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 987-991.	0.7	3
170	Modulation of Interleukins in Sepsis-Associated Clotting Disorders. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 34-39.	0.7	3
171	Patients With a History of Idiopathic Deep Venous Thrombosis Have Long-Term Increased Levels of Inflammatory Markers and Markers of Endothelial Damage. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 124-131.	0.7	20
172	Biomarker profiling of plasma samples utilizing RANDOX biochip array technology. <i>International Angiology</i> , 2017, 36, 499-504.	0.4	8
173	Prevalence of metabolic syndrome in patients undergoing total joint arthroplasty and relevance of biomarkers. <i>International Angiology</i> , 2017, 36, 136-144.	0.4	4
174	Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 743-748.	0.7	14
175	Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 520-527.	0.7	41
176	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
177	Are Inflammatory Biomarkers Increased in Varicose Vein Blood?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 656-664.	0.7	41
178	Levels of Matrix Metalloproteinases in Arthroplasty Patients and Their Correlation With Inflammatory and Thrombotic Activation Processes. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 441-446.	0.7	9
179	Inflammation and Hemostatic Activation may Contribute to Postsurgical Thrombosis in Patients With Bladder Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 314-321.	0.7	3
180	Perioperative Factors and Their Effect on the Fibrinolytic System in Arthroplasty Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 274-279.	0.7	10

#	ARTICLE	IF	CITATIONS
181	Restoration of Normal Prothrombin Time/International Normalized Ratio With Fresh Frozen Plasma in Hypocoagulable Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 85-91.	0.7	4
182	Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 372-376.	0.7	9
183	Comparison of Ufh and Enoxaparin Originated from Bovine, Ovine and Porcine Mucosa with Functional Coagulation Assays. <i>Blood</i> , 2016, 128, 5020-5020.	0.6	3
184	Porcine and Ovine Mucosal Heparins and Their Depolymerized Derivatives Are Comparable in Contrast to Their Bovine Equivalents. <i>Blood</i> , 2016, 128, 5027-5027.	0.6	1
185	Extracellular Nucleosome Levels in the Etiopathogenesis of Sepsis Associated Coagulopathy. <i>Blood</i> , 2016, 128, 564-564.	0.6	1
186	Persistent Prothrombotic State in Atrial Fibrillation Despite Use of Novel Oral Anti-Coagulants. <i>Blood</i> , 2016, 128, 3832-3832.	0.6	0
187	Comparative Studies on the Anticoagulant Actions of Recombinant Thrombomodulin and Heparin and Their Neutralization By FEIBA As Measured By Thromboelastography. <i>Blood</i> , 2016, 128, 2608-2608.	0.6	1
188	International Normalized Ratio Relevance to the Observed Coagulation Abnormalities in Warfarin Treated and Those with Disseminated Intravascular Coagulation. <i>Blood</i> , 2016, 128, 3797-3797.	0.6	0
189	Idarucizumab, a Specific Antidote for Dabigatran, Cross-React with Melagatran and May Also Interact with Other Benzamidine-Containing Compounds. <i>Blood</i> , 2016, 128, 3836-3836.	0.6	0
190	Comparative Anticoagulant Effects of Recombinant Thrombomodulin, Antithrombin, and Unfractionated Heparin, Hematological Implications. <i>Blood</i> , 2016, 128, 4974-4974.	0.6	0
191	Dabigatran Neutralizing Antibody, Idarucizumab, Exhibits Procoagulant and Platelet Activation Responses in Whole Blood. Potential Clinical Implications. <i>Blood</i> , 2016, 128, 2622-2622.	0.6	0
192	Biomarkers of Inflammation and Infection in Sepsis Associated Disseminated Intravascular Coagulation and Their Prognostic Role. <i>Blood</i> , 2016, 128, 1412-1412.	0.6	1
193	Platelet Activation in End-Stage Renal Disease Is Mediated By Extracellular Nucleosomes That Originate from White Blood Cells. <i>Blood</i> , 2016, 128, 4909-4909.	0.6	0
194	Increased Extracellular Nucleosome Levels and Microparticles in Atrial Fibrillation Patients Compared to the Age-Matched Normal Population. <i>Blood</i> , 2016, 128, 4912-4912.	0.6	0
195	Immunoenzymatic and Biochip Array Profiling of the Biomarkers of Inflammation and Hemostatic Activation Processes in ESRD. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 405-411.	0.7	2
196	Making headway in anticoagulant and antiplatelet therapy. <i>Nature Reviews Cardiology</i> , 2015, 12, 70-71.	6.1	8
197	Differentiation of Generic Enoxaparins Marketed in the United States by Employing NMR and Multivariate Analysis. <i>Analytical Chemistry</i> , 2015, 87, 8275-8283.	3.2	42
198	Characterization of the Antithrombotic Fingerprint of the Branded and Copies of the Low-Molecular-Weight Enoxaparin Using Thrombin Generation Assay. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 697-704.	0.7	0

#	ARTICLE	IF	CITATIONS
199	Dysregulation of Inflammatory and Hemostatic Markers in Sepsis and Suspected Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 120-127.	0.7	19
200	Pre-Existence of Prothrombotic State in Patients with Atrial Fibrillation Despite Therapy with New and Traditional Anti-Coagulant Drugs. <i>Blood</i> , 2015, 126, 4731-4731.	0.6	1
201	Resourcing of Heparin and Low Molecular Weight Heparins from Bovine, Ovine, and Porcine Origin. Studies to Demonstrate the Biosimilarities. <i>Blood</i> , 2015, 126, 4733-4733.	0.6	8
202	Prevalence of Metabolic Syndrome in Patients with End Stage Renal Disease and Relevance of Biomarkers. <i>FASEB Journal</i> , 2015, 29, 763.4.	0.2	1
203	Increased Biomarkers of Metabolic Syndrome in Total Joint Arthroplasty Patients. <i>FASEB Journal</i> , 2015, 29, 766.8.	0.2	0
204	Dilute Russell's Viper Venom Clotting Time (DRVVT) is Useful for the Routine Monitoring of Newer Non-Vitamin K Anticoagulants. <i>FASEB Journal</i> , 2015, 29, 609.9.	0.2	0
205	Comparative Studies on the Molecular and Functional Profile of Sheep Mucosal Derived Enoxaparin. <i>FASEB Journal</i> , 2015, 29, 927.7.	0.2	0
206	Thrombomodulin Inhibits Tissue factor Mediated Thrombin Generation in blood and Prothrombin Complex Concentrates. <i>FASEB Journal</i> , 2015, 29, 609.11.	0.2	0
207	Bovine and Porcine Mucosal Heparins Exhibit Similar Biologic Profiles. <i>FASEB Journal</i> , 2015, 29, 610.4.	0.2	0
208	Effect of Recombinant Lubricin on Coagulation Parameters in Human Blood. <i>FASEB Journal</i> , 2015, 29, 609.8.	0.2	0
209	Expression of osteopontin and markers of inflammation in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15122-e15122.	0.8	0
210	Metabolic syndrome marker profile in patients with hepatocellular carcinoma HCC.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22255-e22255.	0.8	0
211	A Generic Version of Recombinant FVIIa Is Similar to the Branded Product (NovoSeven). <i>Blood</i> , 2015, 126, 4746-4746.	0.6	0
212	Role of Platelet Activation in the Pathogenesis of Heart Failure in End-Stage Renal Disease Patients. <i>Blood</i> , 2015, 126, 4636-4636.	0.6	0
213	Upregulation of Microparticles, Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin in End Stage Renal Disease. <i>Blood</i> , 2015, 126, 2312-2312.	0.6	0
214	Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188) As Studied in Agonist Induced Platelet Aggregation Systems. <i>Blood</i> , 2015, 126, 1037-1037.	0.6	0
215	The Potential Role of Ferritin in Relation to Inflammatory and Metabolic Syndrome Biomarkers in Patients Undergoing Total Joint Arthroplasty of the Hip or Knee. <i>Blood</i> , 2015, 126, 4560-4560.	0.6	0
216	Recombinant Thrombomodulin Inhibits Tissue Factor Mediated Thrombin Generation in Blood Plasma and Is Modulated By Prothrombin Complex Concentrates. <i>Blood</i> , 2015, 126, 2303-2303.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Cellular and Functional Characterization of Microparticles in Sepsis-Associated Coagulopathy. Blood, 2015, 126, 2297-2297.	0.6	0
218	Baseline Thrombin Generation Markers and Functional Antithrombin Levels in Sepsis Associated Coagulopathies Are Predictive of the Severity of Pathogenesis. Blood, 2015, 126, 4693-4693.	0.6	0
219	Biomarkers of Hemostatic Dysregulation, Inflammation, and Infection in Patients Diagnosed with Sepsis Associated Coagulopathy. Blood, 2015, 126, 2281-2281.	0.6	1
220	Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 678-686.	0.7	9
221	Comparative Biochemical and Functional Studies on a Branded Human Recombinant Factor VIIa and a Biosimilar Equivalent Product. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 565-572.	0.7	6
222	Drug Interactions of Newer Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban with Routinely Used Nonanticoagulant/Antiplatelet Drugs. Blood, 2014, 124, 4267-4267.	0.6	6
223	Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban. Blood, 2014, 124, 5084-5084.	0.6	1
224	Usefulness of Dilute Russell's Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants. Blood, 2014, 124, 1537-1537.	0.6	0
225	Use of Thrombin Generation Assay As Tool for the Evaluation of the Antithrombotic Sameness of Enoxaparin Copies. Blood, 2014, 124, 5092-5092.	0.6	0
226	Recombinant Factor VIIa (rFVIIa) Mediated Activation of Prothrombin Complex Concentrates (PCCs). Studies on the Comparison of Novoseven with a Biosimilar Product. Blood, 2014, 124, 5108-5108.	0.6	0
227	Augmentation of the Anticoagulant Effects of Heparin By a Tri-Block Polymer MST-188. Blood, 2014, 124, 5080-5080.	0.6	0
228	Comparative Studies on Branded Enoxaparin and a US Generic Version of Enoxaparin. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 261-267.	0.7	6
229	Metabolic differences of current thienopyridine antiplatelet agents. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 307-317.	1.5	8
230	Update on the safety and bioequivalence of biosimilars – focus on enoxaparin. Drug, Healthcare and Patient Safety, 2013, 5, 133.	1.0	26
231	Immune-Mediated Activation Of Coagulation In Patients With Stevens Johnson Syndrome/Toxic Epidermal Necrolysis. Blood, 2013, 122, 1117-1117.	0.6	1
232	Effect Of Dabigatran and Rivaroxiban On Thrombomodulin Mediated Activation Of Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAFI). Potential Clinical Implications. Blood, 2013, 122, 3641-3641.	0.6	3
233	Neutralization Of Hemorrhage Induced By Direct Factor Xa and Thrombin Inhibitors In a Rat Model. Blood, 2013, 122, 3644-3644.	0.6	1
234	Effect Of Purified Poloxamer 188 & Various Dextrans On Erythrocyte Sedimentation Rate In Healthy Subjects and Patients With Sickle Cell Disease. Blood, 2013, 122, 4764-4764.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs. Blood, 2013, 122, 4804-4804.	0.6	2
236	Biochemical and pharmacological differentiation of dabigatran, apixaban and rivaroxaban. FASEB Journal, 2013, 27, lb504.	0.2	0
237	Comparative hemorrhagic studies on dabigatran, apixaban and rivaroxaban in a rat tail bleeding model. FASEB Journal, 2013, 27, lb505.	0.2	0
238	Compositional differences in commercial available prothrombin complex concentrates and their activation by tissue factor. FASEB Journal, 2013, 27, 871.1.	0.2	0
239	A Comparison Of Hemostatic and Inflammatory Markers In Overt and Non-Overt DIC. Blood, 2013, 122, 3577-3577.	0.6	0
240	Increased Levels Of Tissue Factor, Adhesion Molecules, Nitric Oxide and Adiponectin In End Stage Renal Disease. A Complex Interplay. Blood, 2013, 122, 4742-4742.	0.6	0
241	Thrombotic Biomarker Profiling Of Plasma Samples From Patients Undergoing Bypass Surgery Using Protein Chip Array. Blood, 2013, 122, 3579-3579.	0.6	0
242	Dysregulation Of Thrombotic and Hemostatic Factors In End Stage Renal Disease. Blood, 2013, 122, 4793-4793.	0.6	0
243	Oral Anti-Factor Xa and Factor IIa Agent Mediated Inhibition Of Tissue-Factor Mediated Generation Of Thrombin In Prothrombin Complex Concentrates. Blood, 2013, 122, 4810-4810.	0.6	0
244	Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants. Blood, 2013, 122, 3642-3642.	0.6	1
245	Comparative Studies Of Purified Poloxamer 188 Using ClotBased and Viscoelastic Measurements Of Coagulation. Blood, 2013, 122, 4770-4770.	0.6	0
246	Harry L. Messmore, Jr., MD (1922-2011). Seminars in Thrombosis and Hemostasis, 2012, 38, 753-754.	1.5	0
247	Gender-based differences in hemostatic responses. Personalized Medicine, 2012, 9, 191-199.	0.8	1
248	Old Versus New Oral Anticoagulants: Focus on Pharmacology. Annual Review of Pharmacology and Toxicology, 2012, 52, 79-99.	4.2	71
249	US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins. Journal of Thrombosis and Thrombolysis, 2012, 33, 230-238.	1.0	10
250	Comparative Antithrombotic and Bleeding Effects of Two U.S. Generic Enoxaparins. Blood, 2012, 120, 1172-1172.	0.6	1
251	Dysregulation of Inflammatory and Hemostatic Markers in Sepsis Associated Disseminated Intravascular Coagulation.. Blood, 2012, 120, 2223-2223.	0.6	1
252	Effect of Heparin and Its Derivatives On the Progression of Tumor Growth in Mouse Lewis Lung Carcinoma Model.. Blood, 2012, 120, 2274-2274.	0.6	1

#	ARTICLE	IF	CITATIONS
253	A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation. <i>Blood</i> , 2012, 120, 24-24.	0.6	2
254	Biomarker Profiling of Bladder Cancer Patients Undergoing Radical Cystectomy. Relevance of Thrombotic and Inflammatory Processes. <i>Blood</i> , 2012, 120, 3405-3405.	0.6	1
255	Compositional Differences in Commercially Available Prothrombin Complex Concentrates. <i>Blood</i> , 2012, 120, 4391-4391.	0.6	7
256	Biomarker profiling of bladder cancer patients undergoing radical cystectomy: Relevance of thrombotic and inflammatory processes.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15008-e15008.	0.8	1
257	Non-antithrombin affinity Semuloparin and it's component oligosaccharides release endogenous TFPI in a molecular weight dependent fashion. <i>FASEB Journal</i> , 2012, 26, 832.5.	0.2	0
258	Tissue factor mediated generation of thrombin in prothrombin complexes is inhibited by anti-Xa based parenteral and oral agents but not by parenteral and oral antithrombin agents. Results from proteomic profiling using protein chip arrays. <i>FASEB Journal</i> , 2012, 26, lb537.	0.2	0
259	Evaluation of the Antithrombotic and Hemorrhagic Effects of a Novel Ultra Low Molecular Weight Heparin (ULMWH). <i>FASEB Journal</i> , 2012, 26, 832.3.	0.2	0
260	Effect of Dabigatran and Rivaroxaban on thrombomodulin mediated activation of protein C and thrombin activated fibrinolysis inhibitor (TAFI). <i>FASEB Journal</i> , 2012, 26, 832.7.	0.2	2
261	Comparative studies on the effect of newer oral anticoagulants on platelet aggregation. Pharmacological and developmental implications. <i>FASEB Journal</i> , 2012, 26, lb497.	0.2	0
262	Further Studies on the Isolation and Characterization of Heparin Contaminants Isolated From Recalled Batches of Unfractionated Heparin. <i>FASEB Journal</i> , 2012, 26, 1115.18.	0.2	0
263	Despite Pharmaceutical Equivalence, Generic Versions of Enoxaparin May Differ in Their Pharmacodynamic Actions. Potential Clinical Implications. <i>FASEB Journal</i> , 2012, 26, 832.6.	0.2	0
264	The effect of tissue factor pathway inhibitor release and interactions with growth factors on the antitumor effects of ultra low molecular weight heparin semuloparin.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13117-e13117.	0.8	0
265	Effect of heparin and its derivatives on the progression of tumor growth in mouse Lewis lung carcinoma model.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13115-e13115.	0.8	0
266	Variations in the Circulating Heparin Levels During Maintenance Hemodialysis in End Stage Renal Disease Patients. <i>Blood</i> , 2012, 120, 3412-3412.	0.6	0
267	Comparative Studies On Branded Enoxaparin and a US Generic Version of Enoxaparin.. <i>Blood</i> , 2012, 120, 2264-2264.	0.6	0
268	Population Based Differences in the Anticoagulant and Antiprotease Responses of Newer and Oral Anticoagulant Drugs. <i>Blood</i> , 2012, 120, 3421-3421.	0.6	0
269	Defibrotide Interactions with Newer Oral Anticoagulants and Antithrombotic Agents. <i>Blood</i> , 2012, 120, 3411-3411.	0.6	0
270	Thrombin Generation Mediators and Markers in Sepsis Associated Coagulopathy and Their Modulation by Recombinant Thrombomodulin. <i>Blood</i> , 2012, 120, 1131-1131.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Tissue Factor Mediated Activation of Prothrombin Complex Concentrates (PCCs) Is Differently Inhibited by Dabigatran, Rivaroxaban and Apixaban. Potential Clinical Implications. Blood, 2012, 120, 3410-3410.	0.6	1
272	A Multicenter Pilot Study to Estimate the Prevalence of Bovine and Human Coagulation Antibodies in the General US Population. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 164-170.	0.7	1
273	An Open Label, Non-randomized, Prospective Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars in Healthy Volunteers. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 66-69.	0.7	8
274	Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism. Thrombosis Journal, 2011, 9, 5.	0.9	10
275	Thrombin Generation Inhibition by Newer Anti Xa and Anti IIa Drugs in Prothrombin Complex Concentrates: Relevance to Endogenous Modulation of Thrombogenesis. Blood, 2011, 118, 1196-1196.	0.6	3
276	Inflammatory and Thrombotic Mediators in Small Cell Lung Carcinoma: Potential Role in Thromboembolic Complications. Blood, 2011, 118, 2294-2294.	0.6	1
277	Biochip Array Analysis of Various Mediators of Inflammation in Disseminated Intravascular Coagulation. Blood, 2011, 118, 2302-2302.	0.6	1
278	Protein Chip Array Profiling of Molecular Variants of Hirudins Using Surface Enhanced Laser Desorption Ionization (SELDI) Technique. FASEB Journal, 2011, 25, 1002.18.	0.2	0
279	Increased prevalence of Anti-Heparin Platelet factor 4 antibodies in patients with sepsis associated Disseminated Intravascular Coagulation. FASEB Journal, 2011, 25, 1002.1.	0.2	0
280	Identification of Unique Biomarkers in Sepsis Associated Coagulopathy. Blood, 2011, 118, 1237-1237.	0.6	0
281	Pharmacodynamic Differences in the Two Generic Brands of Enoxaparin. Blood, 2011, 118, 1251-1251.	0.6	0
282	Should Generic Versions of Low Molecular Weight Heparins Be Considered As Generic or Biosimilar Drugs. A Regulatory Dilemma. Blood, 2011, 118, 4328-4328.	0.6	0
283	Selection of a Suitable Rapid Turn Around and Sensitive Test for the Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran,. Blood, 2011, 118, 3363-3363.	0.6	0
284	Comparative Studies on the HIT Antibody Mediated Platelet Aggregation / Serotonin Release by Synthetic Pentasaccharide and Two Chemoenzymatically Synthesized Heptasaccharides. Blood, 2011, 118, 2231-2231.	0.6	0
285	Product Associated Variation in Generic Enoxaparin. Potential Clinical Implications. Blood, 2011, 118, 1249-1249.	0.6	0
286	Cross Reactivity of Natural Hirudin Compared to the Recombinant Hirudins with Sheep Anti Hirudin Antibody. Blood, 2011, 118, 4321-4321.	0.6	8
287	Thrombin Generation Mediators and Markers in Sepsis Associated Coagulopathy,. Blood, 2011, 118, 3341-3341.	0.6	0
288	Comparison of the Pharmacokinetic and Pharmacodynamic Behavior of Branded and Generic Enoxaparin in Non-Human Primates. Blood, 2011, 118, 1254-1254.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Thrombotic and Inflammatory Mediators in Cancer Patients Are Downregulated by Enoxaparin. Biochip and Protein Array Analysis. Blood, 2011, 118, 713-713.	0.6	0
290	Unlike Heparins Newer Oral Anticoagulants Do Not Interact with HIT Antibodies and Maybe Useful in the Longterm Anticoagulant Management of Heparin Compromised Patients. Blood, 2011, 118, 2317-2317.	0.6	1
291	Markers of Thrombogenesis Activation and Endothelial Dysfunction in End Stage Renal Disease. Blood, 2011, 118, 1151-1151.	0.6	0
292	Generic Low Molecular Weight Heparins May Not Have the Same Safety & Efficacy Profile As the Branded Low Molecular Weight Heparins in Acute Coronary Syndrome. Blood, 2011, 118, 2308-2308.	0.6	0
293	Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants. Blood, 2011, 118, 4326-4326.	0.6	0
294	Molecular Mimicry in the Adulteration of Heparins. Chemical Basis for the Development of Oversulfated Chondroitin Sulfate and Related Contaminants. Blood, 2011, 118, 4322-4322.	0.6	0
295	Biological Activities of Two Ultra-Low Molecular Weight Heparins, Semuloparin and Bemiparin, Reveal That a Common Potency Standard Is Inadequate. Blood, 2011, 118, 4324-4324.	0.6	0
296	Inflammatory and Procoagulant Cytokine Levels During Pregnancy As Predictors of Adverse Complications. Blood, 2011, 118, 2296-2296.	0.6	5
297	Apixaban to prevent venous thromboembolism after knee replacement. Lancet, The, 2010, 375, 779-780.	6.3	2
298	An Open Label, Non Randomized, Prospective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.. Blood, 2010, 116, 1086-1086.	0.6	1
299	Immune Response Following Exposures to Topical Bovine Thrombin Does Not Impair Hemostasis. Blood, 2010, 116, 1401-1401.	0.6	2
300	Cross–Reactivity of Rabbit Anti–Bovine Thrombin IgGs with a Human Plasma Derived Thrombin Preparation (Evithrom &,c). FASEB Journal, 2010, 24, 951.11.	0.2	0
301	Potency Adjustment of Unfractionated Heparins to Harmonize the USP and WHO Standardization. Impact on Anticoagulant Practice in the US. FASEB Journal, 2010, 24, 951.8.	0.2	0
302	Biochip Array Analysis of Various Mediators of Inflammation in Disseminated Intravascular Coagulation. FASEB Journal, 2010, 24, 951.4.	0.2	0
303	Comparative Studies on Branded Dalteparin with Two Generic Versions: Hepagumin and Fluzepamin. FASEB Journal, 2010, 24, 951.7.	0.2	0
304	Quantification of von Willebrand Factor and von Willebrand Factor Propeptide in Patients with End Stage Renal Disease. FASEB Journal, 2010, 24, 1030.4.	0.2	0
305	Baseline and Serial Microparticle Concentration Analysis in Elderly Patients with Acute Hip Fracture Treated with Heparins. FASEB Journal, 2010, 24, 1b430.	0.2	0
306	Elevated Levels of Circulating Microparticles in Disseminated Intravascular Coagulation and Their Impact on the Inflammatory Process. FASEB Journal, 2010, 24, 951.13.	0.2	0

#	ARTICLE	IF	CITATIONS
307	Differential Inhibition of Arachidonic Acid Mediated Aggregation of Platelets by Branded and Generic Argatroban Preparations. Blood, 2010, 116, 5131-5131.	0.6	0
308	Dysregulation of Inflammatory and Hemostatic Markers In Disseminated Intravascular Coagulation.. Blood, 2010, 116, 3656-3656.	0.6	0
309	Measurements of Prothrombin Fragment 1.2 In Urine and Blood to Assess Hypercoagulability In Preeclampsia. Blood, 2010, 116, 3174-3174.	0.6	0
310	Upregulation of Inflammatory Mediators In End-Stage Renal Disease as Measured Via Biochip Array Technology. Blood, 2010, 116, 5186-5186.	0.6	0
311	Differential Prevalence of Anti-Heparin-Platelet Factor 4 Antibodies In Elderly Patients with Acute Hip Fracture Undergoing Orthopaedic Surgery and Anticoagulated with Unfractionated Heparin and Enoxaparin. Blood, 2010, 116, 4217-4217.	0.6	0
312	Comparative Studies on An Anti-Xa Enriched Ultra Low Molecular Weight Heparin with Bemiparin. Blood, 2010, 116, 4394-4394.	0.6	0
313	Biochip Array Profiling of Inflammatory Cytokines and Growth Factors In End-Stage Renal Disease: Hematological Implications?. Blood, 2010, 116, 5184-5184.	0.6	0
314	Comparison of Seven Generic Enoxaparins with Lovenox® on In Vitro Cross-Reactivity with Antibodies From Heparin Induced Thrombocytopenia.. Blood, 2010, 116, 1105-1105.	0.6	5
315	Comparison of Branded Enoxaparin (Lovenox) and a Biosimilar Version of Enoxaparin (Fibrinox). Blood, 2010, 116, 4385-4385.	0.6	0
316	Non-Pathogenic Anti-Heparin/PF4 Antibodies Generated by Low Molecular Weight Heparins Mediate Procoagulant Effects.. Blood, 2010, 116, 1091-1091.	0.6	0
317	Upregulation of Von Willebrand Factor, Von Wilebrand Factor Propeptide, and ADMATS-13 In End-Stage Renal Disease. Blood, 2010, 116, 5189-5189.	0.6	0
318	Cross Reactivity of Rabbit Anti-Recothrom (Human Recombinant Thrombin) Antibodies with Molecular Variants of Human Thrombin, and Various Bovine Thrombin Preparations. Blood, 2010, 116, 4418-4418.	0.6	0
319	Activation Markers of Thrombogenesis and Endothelial Dysfunction In End-Stage Renal Disease. Blood, 2010, 116, 5183-5183.	0.6	0
320	Effect of Heparin:PMX60056 Complexes on Platelet Aggregation Induced by ADP or HIT Antibody. Blood, 2010, 116, 4386-4386.	0.6	0
321	Generic and Branded Versions of Argatroban Exhibit Differential Anticoagulant Effects In Whole Blood, Plasma Based Assays and Thrombin Generation Assays. Blood, 2010, 116, 5129-5129.	0.6	0
322	Differential Modulation of Cytokines by VEGF In End Stage Renal Disease. Blood, 2010, 116, 5187-5187.	0.6	1
323	Generic Versions of Low Molecular Weight Heparin May Not Have the Same Safety-Efficacy Profile as the Branded Low Molecular Weight Heparins In Acute Coronary Syndrome.. Blood, 2010, 116, 1098-1098.	0.6	0
324	Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs. Blood, 2010, 116, 3334-3334.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs.. Blood, 2009, 114, 4180-4180.	0.6	1
326	Bioavailability of oversulfated chondroitin sulfate in rats. Pharmacological implications in contaminated heparins. FASEB Journal, 2009, 23, LB401.	0.2	0
327	Biomarker profiling in elderly patients with acute hip fracture: modulation by prophylactic dosage of enoxaparin. FASEB Journal, 2009, 23, 569.1.	0.2	0
328	Species variation in the heparin contaminant mediated generation of kallikrein. FASEB Journal, 2009, 23, 569.14.	0.2	0
329	Coagulation profiling of class B vendor cats with reference to serine protease inhibitors. FASEB Journal, 2009, 23, 569.12.	0.2	0
330	Generic versions of argatroban can be differentiated from branded argatroban using a thrombin generation assay (TGA). FASEB Journal, 2009, 23, 575.1.	0.2	0
331	Neutralization of Hemorrhagic and Antithrombotic Activities of Heparins by a Novel Salicylamide Derivative. FASEB Journal, 2009, 23, 569.6.	0.2	1
332	Does Contaminated Heparin Lead to a Higher Prevalence of HIT Antibodies?. FASEB Journal, 2009, 23, 569.10.	0.2	0
333	Differential thrombin generation inhibition by branded and generic low molecular weight heparins (LMWHs) as studied using a fluorescence substrate based kinetic method. FASEB Journal, 2009, 23, 569.3.	0.2	0
334	Differential augmentation of the anticoagulant responses by newly developed oral anti-Xa and anti-IIa drugs in patients with liver disease. FASEB Journal, 2009, 23, LB383.	0.2	0
335	Decreased Immunogenicity of Purified Topical Bovine Thrombin Preparations.. Blood, 2009, 114, 4209-4209.	0.6	2
336	Oversulfated Chondroitin Sulfate Does Not Cause Augmentation in HIT Antibody Mediated Heparin-Induced Platelet Aggregation (HIPA).. Blood, 2009, 114, 2417-2417.	0.6	19
337	Higher Prevalence of Heparin-Induced Thrombocytopenia Antibodies in Asian Indian Population: Is This Due to Contaminated Heparin?. Blood, 2009, 114, 4182-4182.	0.6	0
338	Gender-Based Differences in Hemostatic Responses. Implications in Effective Anticoagulant Management.. Blood, 2009, 114, 2103-2103.	0.6	0
339	Persistent Inhibition of Thrombin Generation After Intravenous Administration of Enoxaparin in Primates.. Blood, 2009, 114, 2095-2095.	0.6	0
340	Pharmacodynamic Differences of An Anti-Xa Enriched Low Molecular Weight Heparin, AVE 5026 in Comparison to Enoxaparin and Unfractionated Heparin.. Blood, 2009, 114, 4171-4171.	0.6	0
341	Cross-Reactivity of Rabbit Anti-Bovine Thrombin IgGs with Human $\hat{\pm}$ -Thrombin and a Recombinant Version of Human Thrombin (Recothrom $\hat{\pm}$, \hat{c}).. Blood, 2009, 114, 4211-4211.	0.6	0
342	Prevalence of Anti-Heparin Platelet Factor 4 Antibodies in Patients with Disseminated Intravascular Coagulation.. Blood, 2009, 114, 2094-2094.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Thrombin Generation Assessment in Platelet Rich Plasma Offers Additional Criteria for Low Molecular Weight Heparin Antithrombotic Fingerprint Characterization.. Blood, 2009, 114, 4177-4177.	0.6	0
344	Protease Generation by Chondroitin Sulfate, Semisynthetic OSCS Preparations and Contaminants Isolated From Heparin.. Blood, 2009, 114, 3133-3133.	0.6	0
345	Comparative Studies On Heparin Contaminant Interactions with Normals, Liver Disease, Heparin Treated and Oral Anticoagulant Treated Patients Plasma.. Blood, 2009, 114, 2093-2093.	0.6	0
346	Oversulfated Chondroitin Sulfate Is Not the Sole Contaminant in Recalled Heparin Preparations.. Blood, 2009, 114, 1070-1070.	0.6	0
347	Enoxaparin Produces Sustained Antithrombotic Effects in Comparison to Fondaparinux and Rivaroxaban: Clinical Implications.. Blood, 2009, 114, 3128-3128.	0.6	0
348	Contaminants Isolated From Recalled Heparin Are Not All the Same: Clinical Implications.. Blood, 2009, 114, 1069-1069.	0.6	0
349	Are All Low Molecular Weight Heparins Equivalent in the Management of Venous Thromboembolism?. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 385-392.	0.7	13
350	Survival of Heparins, Oral Anticoagulants, and Aspirin after the Year 2010. Seminars in Thrombosis and Hemostasis, 2008, 34, 058-073.	1.5	63
351	Identification of a unique plasma biomarker from patients undergoing total hip or knee replacement surgery utilizing protein chip array methods. FASEB Journal, 2008, 22, 606-606.	0.2	1
352	Defibrotide Interactions with Anticoagulant Drugs. Developmental Implications.. FASEB Journal, 2008, 22, 1118.12.	0.2	0
353	Differential Prevalence of Anti-Heparin PF4 Immunoglobulin Subtypes in Patients Treated with Reviparin, Enoxaparin, and Certoparin. Implications in HIT Pathogenesis.. FASEB Journal, 2008, 22, 1118.13.	0.2	0
354	Pharmacokinetics of Defibrotide in Non-Human Primates is Dose Dependent.. FASEB Journal, 2008, 22, 1118.11.	0.2	0
355	Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives. FASEB Journal, 2008, 22, 1118.5.	0.2	0
356	Neutralization of the Anticoagulant and Anti- α Effects of Fondaparinux and Idraparinux by a Novel Synthetic Antagonist. Pharmacologic Implications. FASEB Journal, 2008, 22, .	0.2	1
357	Comparative Anticoagulant Effects of Suledoxide and Enoxaparin in Citrated Whole Blood. FASEB Journal, 2008, 22, 1118.8.	0.2	0
358	Effect of Heparin and Low Molecular Weight Heparin on the Regulation of Microparticle in Atrial Fibrillation. FASEB Journal, 2008, 22, 1118.3.	0.2	0
359	Differential Interaction of Anti-Heparin Platelet Factor 4 Antibodies with Branded and Generic Versions of Low Molecular Weight Heparins. Pathophysiologic and Bioequivalence Implications.. FASEB Journal, 2008, 22, 1118.4.	0.2	0
360	Molecular Profiling of Generic Versions of the Low Molecular Weight Heparin Enoxaparin and Their Digestion by Heparinase-1. FASEB Journal, 2008, 22, 1118.6.	0.2	0

#	ARTICLE	IF	CITATIONS
361	AVE5026: A New Hemisynthetic Ultra Low Molecular Weight Heparin with Enriched Anti-Xa Activity and Enhanced Antithrombotic Activity for Management of Cancer Associated Thrombosis. Blood, 2008, 112, 4046-4046.	0.6	0
362	Increased Levels of Anaphylatoxin (C5a) and Bradykinin in End-Stage Renal Disease Patients on Maintenance Hemodialysis. Potential Relevance to Heparin Mediated Hemodynamic Responses. Blood, 2008, 112, 4079-4079.	0.6	0
363	Defibrotide Augments the Anticoagulant Actions of Heparin and Low Molecular Weight Heparins. Blood, 2008, 112, 4086-4086.	0.6	0
364	Increased Procalcitonin Levels in End Stage Renal Disease and Chronic Kidney Disease as An Indicator of Inflammatory Activation. Blood, 2008, 112, 5472-5472.	0.6	0
365	Fibrinokinetic Deficit in Chronic Kidney Disease and End Stage Renal Disease Patients Contributes to the Hemostatic Abnormalities. Blood, 2008, 112, 4078-4078.	0.6	0
366	Relative Immunologic Potential of Bovine Prothrombin and Purified Thrombins. Blood, 2008, 112, 5463-5463.	0.6	0
367	Increased Antithrombotic and Bleeding Effects of Contaminated Heparins; Hematological Implications. Blood, 2008, 112, 3021-3021.	0.6	0
368	A Higher Prevalence of HIT Antibodies in Patients May Be Due to Contaminated Heparin. Blood, 2008, 112, 3022-3022.	0.6	0
369	Selective Serotonin Reuptake Inhibitors Influence Agonist-Induced Platelet Aggregation. Preliminary Results from Comorbidity of Depression and Cardiovascular Disease Study. Blood, 2008, 112, 4556-4556.	0.6	0
370	Molecular and Functional Heterogeneity in Contaminants Isolated from Recalled Heparin. Impact on Anticoagulation and Potential Adverse Reactions. Blood, 2008, 112, 4048-4048.	0.6	4
371	Glanzmann's Thrombasthenia Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE). Blood, 2008, 112, 1236-1236.	0.6	0
372	Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Thrombosis Research, 2007, 119, 653-661.	0.8	20
373	Argatroban is Capable of Passing Through the Blood Brain Barrier. Potential Implications in the Management of Thrombotic Stroke. FASEB Journal, 2007, 21, A397.	0.2	1
374	Hemodialysis Mediated Upregulation of Myeloperoxidase in End Stage Renal Disease: Pathophysiologic Implications. FASEB Journal, 2007, 21, A438.	0.2	2
375	Factor Xa Inhibitors Can Be Differentiated in Xa, IIa and Microparticle Generation and Other Whole Blood Based Assays.. Blood, 2007, 110, 931-931.	0.6	1
376	Inhibition of Heparinase I by Defibrotide: Potential Clinical Implications. FASEB Journal, 2007, 21, A1124.	0.2	0
377	Prevalence of Non-specific Cross-reactive Epitopes to Bovine Factor Va Light Chain Fragments in Normal and Patient Plasma. FASEB Journal, 2007, 21, A1124.	0.2	0
378	Antiinflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors. Experimental and Clinical Observations. FASEB Journal, 2007, 21, A1127.	0.2	0

#	ARTICLE	IF	CITATIONS
379	A Unique Biomarker Is Associated with the Prevalence of Functional Heparin Induced Thrombocytopenia (HIT) Associated Antibodies: Results from Proteomic (ProteinChip Array) Profiling of ELISA Positive HIT Plasma Samples.. Blood, 2007, 110, 3205-3205.	0.6	0
380	Modulation of Platelet Function by Recombinant Thrombomodulin Hematologic Implications.. Blood, 2007, 110, 3898-3898.	0.6	1
381	Upregulation of Microparticles and CD40 Ligand in Antiphospholipid Syndrome: Potential Implication in Inflammatory Responses and Thrombosis.. Blood, 2007, 110, 1740-1740.	0.6	0
382	Regulation of Microparticles and Adhesion Molecules in Pregnancy. Diagnostic and Pathophysiologic Implications.. Blood, 2007, 110, 1639-1639.	0.6	8
383	Suppression of Markers of Thrombin Generation and Inflammation in Patients Receiving Low Molecular Weight Heparin Compared to Unfractionated Heparin for TEE-Guided Cardioversion of Atrial Fibrillation.. Blood, 2007, 110, 3621-3621.	0.6	0
384	Potency Adjusted Generic Versions of Argatroban Can Be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays.. Blood, 2007, 110, 4007-4007.	0.6	0
385	Reduced Fibrinolysis in the Hepatic Venous Occlusive Disease: Effect of Defibrotide on Plasmin Activity.. Blood, 2007, 110, 1992-1992.	0.6	1
386	Methodologic Variations in the Determinations of Anti-Platelet Factor 4-Heparin Antibodies in Patients Suspected of Having Heparin Induced Thrombocytopenia: Diagnostic and Prognostic Implications.. Blood, 2007, 110, 3206-3206.	0.6	0
387	Compositional Differences in the Oligosaccharide Components of Generic Versions of Enoxaparin and Dalteparin.. Blood, 2007, 110, 3999-3999.	0.6	0
388	In Vitro Characterization of the Neutralization of Unfractionated Heparin and Low Molecular Weight Heparin by Novel Salicylamide Derivatives.. Blood, 2007, 110, 1869-1869.	0.6	1
389	Functional Microparticles Are up Regulated in Patients with Anti-Heparin/Platelet Factor 4 Antibodies: A Potential Mechanism of Thrombogenesis in the Heparin-Induced Thrombocytopenia Syndrome.. Blood, 2007, 110, 2105-2105.	0.6	0
390	Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 389-396.	0.7	348
391	Update on the clinical applications of argatroban. Future Cardiology, 2006, 2, 403-414.	0.5	1
392	Product Individuality of Commercially Available Low-Molecular-Weight Heparins and Their Generic Versions: Therapeutic Implications. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 267-276.	0.7	41
393	Assay Dependent Variations in the Anticoagulant and Protamine Sulfate Neutralization Profiles of Generic Copies of Enoxaparin.. Blood, 2006, 108, 908-908.	0.6	4
394	Differences in the native and heparinase I digestion profiles of a generic enoxaparin: Pharmacologic implications. FASEB Journal, 2006, 20, LB105.	0.2	0
395	Discordance between the 1st and 2nd low molecular weight heparin (LMWH) standards. Implications for dosing. FASEB Journal, 2006, 20, A656.	0.2	0
396	PATHOGENESIS OF ATRIAL FIBRILLATION–POTENTIAL ROLE OF INFLAMMATORY RESPONSE.. FASEB Journal, 2006, 20, A651.	0.2	0

#	ARTICLE	IF	CITATIONS
397	Nitric Oxide and Asymmetric Dimethylarginine Levels in Malignancy Associated Thrombosis and Their Modulation by Anticoagulants.. Blood, 2006, 108, 1477-1477.	0.6	0
398	Increased Levels of Inflammatory Mediators in Lung Cancer and Their Modulation by Oral Anticoagulant Treatment.. Blood, 2006, 108, 892-892.	0.6	0
399	Trypsin Mediated Activation of Thrombin Activatable Fibrinolytic Inhibitor (Carboxypeptidase U): Potential Clinical Implications.. Blood, 2006, 108, 4016-4016.	0.6	0
400	Defibrotide Does Not Cross-React with HIT Antibodies. Implications in the Management of HIT.. Blood, 2006, 108, 1054-1054.	0.6	1
401	Upregulation of Myeloperoxidase in End Stage Renal Disease and Its Modulation by Hemodialysis. A Paradoxical Paradigm.. Blood, 2006, 108, 3838-3838.	0.6	0
402	Inhibition of Heparinase I by Defibrotide with Potential Clinical Implications.. Blood, 2006, 108, 1626-1626.	0.6	0
403	Unfractionated Heparin, Low Molecular Weight Heparins, and Pentasaccharide: Basic Mechanism of Actions, Pharmacology, and Clinical Use. Hematology/Oncology Clinics of North America, 2005, 19, 1-51.	0.9	64
404	Development of Generic Low Molecular Weight Heparins: A Perspective. Hematology/Oncology Clinics of North America, 2005, 19, 53-68.	0.9	12
405	Sticky Platelet Syndrome: The Clinical Spectrum of Thrombosis.. Blood, 2005, 106, 4138-4138.	0.6	1
406	Discordance between the 1st and 2nd Low Molecular Weight Heparin Standards. Implications for Dosing.. Blood, 2005, 106, 4158-4158.	0.6	0
407	Potential Role of ADAMTS13/FXI Complexes in the Pathogenesis of End Stage Renal Disease.. Blood, 2005, 106, 4116-4116.	0.6	0
408	Biochemical and Pharmacologic Profiling of a Novel Dual Acting Antithrombin Agent with Antiprotease and Antiplatelet Actions. Hematologic Implications.. Blood, 2005, 106, 1876-1876.	0.6	0
409	Relative Inhibition of Thrombin Activatable Fibrinolytic Inhibitor by Newly Developed Thrombin Inhibitors: Impact on Bleeding and Antithrombotic Actions.. Blood, 2005, 106, 4051-4051.	0.6	0
410	Von Willebrand Factor Cleaving Protease (ADAMTS-13) Antigen Levels Are Decreased in Patients with Heparin-Induced Thrombocytopenia.. Blood, 2005, 106, 3970-3970.	0.6	4
411	Generic Low-Molecular-Weight Heparins: Some Practical Considerations. Seminars in Thrombosis and Hemostasis, 2004, 30, 703-713.	1.5	60
412	Differentiation of Low-Molecular-Weight Heparins: Impact on the Future of the Management of Thrombosis. Seminars in Thrombosis and Hemostasis, 2004, 30, 89-104.	1.5	24
413	Small-molecule direct antithrombins: argatroban. Best Practice and Research in Clinical Haematology, 2004, 17, 127-138.	0.7	25
414	Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile. Current Pharmaceutical Design, 2004, 10, 983-999.	0.9	47

#	ARTICLE	IF	CITATIONS
415	Development of Prothrombinase Induced Clotting Time (Pefakit Â®, PICT) Assay and its Validation in the Monitoring of Anti-Xa and Anti-FIIa Drugs.. Blood, 2004, 104, 1858-1858.	0.6	0
416	Clinical Evaluation of a New Functional, Plasma-Based Assay for the Detection of Factor V Leiden - the PefakitÂ® APC-R Factor V Leiden Assay.. Blood, 2004, 104, 3997-3997.	0.6	0
417	Synthetic Anti-Xa Drugs Can Be Used for Parenteral Anticoagulation but Not Fondaparinux.. Blood, 2004, 104, 4088-4088.	0.6	8
418	Differential Digestion of Different LMWHs by Heparinase-I and Heparinase-II: Drug Developmental Implications.. Blood, 2004, 104, 4084-4084.	0.6	0
419	Pharmacodynamic and Pharmacokinetic Properties of Enoxaparin. Clinical Pharmacokinetics, 2003, 42, 1043-1057.	1.6	123
420	Management of Thrombotic and Cardiovascular Disorders in the New Millenium. Clinical and Applied Thrombosis/Hemostasis, 2003, 9, 101-108.	0.7	21
421	Prevalence, isotype, and functionality of antiheparinâ€“platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. Thrombosis Research, 2002, 105, 117-123.	0.8	44
422	Practical Issues in the Development of Argatroban: A Perspective. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 56-65.	0.5	18
423	Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opinion on Investigational Drugs, 2001, 10, 1925-1935.	1.9	31
424	Emerging anticoagulant and thrombolytic drugs. Expert Opinion on Emerging Drugs, 2001, 6, 111-135.	1.1	6
425	Pathophysiology of Heparin-Induced Thrombocytopenia. Archives of Pathology and Laboratory Medicine, 2000, 124, 1657-1666.	1.2	58
426	Antithrombin Agents: The New Class of Anticoagulant and Antithrombotic Drugs. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, S45-S55.	0.7	12
427	Pharmacology of argatroban. Expert Opinion on Investigational Drugs, 1999, 8, 625-654.	1.9	26
428	Pharmacologic profile of certoparin. Expert Opinion on Investigational Drugs, 1999, 8, 315-327.	1.9	10
429	Functional Heterogeneity of Antiheparin-Platelet Factor 4 Antibodies: Implications in the Pathogenesis of the HIT Syndrome. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, S32-S37.	0.7	16
430	Low Molecular Weight Heparins: Differences and Similarities in Approved Preparations in the United States. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, S63-S66.	0.7	21
431	Recombinant TFPI and variants:potential implications in the treatment of cardiovascular disorders. Expert Opinion on Investigational Drugs, 1998, 7, 1121-1137.	1.9	4
432	Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clinical Chemistry, 1998, 44, 1845-1853.	1.5	57

#	ARTICLE	IF	CITATIONS
433	Low molecular weight heparins: a developmental perspective. Expert Opinion on Investigational Drugs, 1997, 6, 705-733.	1.9	14
434	Leading Article: Cardiovascular & Renal: Recombinant hirudin: A perspective. Expert Opinion on Investigational Drugs, 1996, 5, 469-494.	1.9	11
435	Recombinant Full-length Tissue Factor Pathway Inhibitor (TFPI) Prevents Thrombus Formation and Retrombosis after Lysis in a Rabbit Model of Jugular Vein Thrombosis. Thrombosis and Haemostasis, 1996, 76, 615-620.	1.8	22
436	Modified crush-avulsion anastomosis model on the rat femoral vein. Microsurgery, 1995, 16, 536-541.	0.6	7
437	Section Review "Cardiovascular & Renal: Recent Developments in Antithrombotic Agents. Expert Opinion on Investigational Drugs, 1995, 4, 389-412.	1.9	19
438	TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thrombosis Research, 1995, 77, 175-185.	0.8	59
439	Heparan sulphate inhibition of cell proliferation induced by TGF β ² and PDGF. Mediators of Inflammation, 1993, 2, 299-302.	1.4	2
440	Low Molecular Weight Heparins. Drugs and Aging, 1992, 2, 406-422.	1.3	11
441	Inhibition of factor X, factor V and prothrombin activation by the bis(lactobionic acid amide) LW10082. FEBS Journal, 1992, 203, 121-125.	0.2	14
442	Global and Molecular Hemostatic Markers in Acute Myeloid Leukemia. American Journal of Clinical Pathology, 1990, 94, 397-403.	0.4	27
443	Thrombin Anion-binding Exosite Interactions with Heparin and Various Polyanions. Annals of the New York Academy of Sciences, 1989, 556, 158-165.	1.8	39
444	Diagnosis of Acute Megakaryoblastic Leukemia by Flow Cytometry and Immunoalkaline Phosphatase Techniques: Utilization of New Monoclonal Antibodies. American Journal of Clinical Pathology, 1988, 89, 247-253.	0.4	24
445	Protein C Antigen Deficiency and Warfarin Necrosis. American Journal of Clinical Pathology, 1986, 86, 653-655.	0.4	64
446	Amidolytic Antifactor Xa Assays in the Laboratory Evaluation of Heparin and Low Molecular Weight Fractions. Seminars in Thrombosis and Hemostasis, 1985, 11, 100-107.	1.5	26
447	A Primate Model (Macaca Mulatta) to Study the Pharmacokinetics of Heparin and Its Fractions. Seminars in Thrombosis and Hemostasis, 1985, 11, 138-154.	1.5	22
448	Validity of Serine Protease Inhibition Tests in the Evaluation and Monitoring of the Effect of Heparin and Its Fractions. Seminars in Thrombosis and Hemostasis, 1985, 11, 112-120.	1.5	16
449	Biochemical and Pharmacologic Studies on the Protamine Interactions with Heparin, Its Fractions and Fragments. Seminars in Thrombosis and Hemostasis, 1985, 11, 176-189.	1.5	50
450	In Vitro Evaluation of Heparin Fractions: Old vs. New Methods. CRC Critical Reviews in Clinical Laboratory Sciences, 1985, 22, 361-389.	1.0	22

#	ARTICLE	IF	CITATIONS
451	Synthetic Peptide Substrates in Hemostatic Testing. CRC Critical Reviews in Clinical Laboratory Sciences, 1983, 19, 71-134.	1.0	11
452	New Perspectives in Coagulation Testing. Clinical Chemistry, 1981, 27, 629-629.	1.5	0
453	Continuous Subcutaneous Heparin Infusion During Pregnancy In A Patient With A Prosthetic Mitral Valve. Clinical And Laboratory Consideration. Thrombosis and Haemostasis, 1981, 46, 1190.	1.8	0
454	Computed Tomography Detection Of Hemorrhagic And Thrombotic Disorders. , 1981, 46, 1435.		0
455	Effect Of Exercise On Platelet Function In Patients With Intermittent Claudication. , 1981, 46, 1405.		0
456	Antiplatelet Actions Of Low Molecular Weight Peptides And Their Derivatives. , 1981, 46, 0193.		0
457	Antithrombotic Properties Of Low Molecular Weight Heparin Fractions From Porcine Mucosal Heparin. Thrombosis and Haemostasis, 1981, 46, 0578.	1.8	0
458	Studies On The Mechanism Of Heparin Induced Thrombocytopenia. Thrombosis and Haemostasis, 1981, 46, 0679.	1.8	1
459	Computerized Axial Tomographic (CAT) Diagnosis Of Vascular Thrombosis And Patency Of Aorto-Coronary Bypass Graft. Thrombosis and Haemostasis, 1981, 46, 0813.	1.8	0
460	The Application Of Computed Tomography In The Diagnosis And Management Of Dissecting Aortic Aneurysms. Thrombosis and Haemostasis, 1981, 46, 0814.	1.8	0
461	Synthetic Peptide Assays For Monitoring The Defects Of Extrinsic And Intrinsic Pathways Of Coagulation: Selection Of A Suitable Substrate. , 1981, 46, 1130.		0
462	Isolation and Partial Characterization of A Novel Circulating Antithrombin. Thrombosis and Haemostasis, 1979, , .	1.8	0
463	Low molecular weight heparins in pregnancy. , 0, , 341-360.		0